Burcon Reports Fiscal 2027 Second Quarter Results
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Burcon NutraScience (BRCNF) reported fiscal 2027 second-quarter revenue of C$1,040,829, reflecting increased protein sales as commercial production expanded. Revenue rose approximately 191% year over year; six-month revenue reached C$2,317,041, up approximately 231%. For the six months ended September 30, 2026, net loss widened to C$7.9 million, or C$0.62 per share, from C$7.0 million, or C$0.56 per share. Operating cash use fell to C$4.4 million from C$4.7 million.
Quarter-end cash was C$1.0 million, with negative working capital of C$15.0 million. Burcon entered a fully drawn loan of up to C$4.2 million with James P Pekar Family Endowment Trust, related to a director. It bears 15% annual interest and matures November 16, 2027. Production improvements and infrastructure challenges constrained quarterly shipments; Burcon said production volumes recovered and accelerated after quarter-end. The company is evaluating further financing.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Major pointRelated-party loan of up to C$4.2 million was fully drawn, including C$1.4 million after quarter-end.
- Moderate pointSecond-quarter revenue rose approximately 191% year over year to C$1,040,829 as protein sales increased.
- Moderate pointSix-month operating cash use declined to C$4.4 million from C$4.7 million in the prior-year period.
- Minor pointSix-month revenue increased approximately 231% year over year to C$2,317,041.
- Minor pointProduction volumes recovered and accelerated after quarter-end, Burcon said.
Negative
- Major pointRelated-party borrowing carries 15% annual interest, payable monthly, and matures November 16, 2027.
- Moderate pointSix-month net loss widened to C$7.9 million (C$0.62 per share) from C$7.0 million (C$0.56 per share).
- Moderate pointQuarter-end liquidity included C$1.0 million cash and C$15.0 million negative working capital, primarily reflecting current loan classifications.
- Moderate pointProduction improvement work and infrastructure challenges constrained second-quarter shipments.
- Minor pointLoan commitment fee adds a C$7,000 cost.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Vancouver, British Columbia--(Newsfile Corp. - November 16, 2026) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein innovation, reported results for the three and six months ended September 30, 2026.
"We are expanding Burcon's commercial business to capture growing customer demand, combining production improvements and additional working capital to drive growth," said Kip Underwood, Chief Executive Officer of Burcon. "Work to enhance plant reliability and efficiency, together with infrastructure challenges, constrained shipments during the second quarter. As expected, production volumes have recovered and accelerated since quarter-end. We are focused on building on those gains, expanding sales and converting our commercial pipeline into sustained revenue growth."
To support its ongoing operations and commercial expansion, Burcon has entered into a loan agreement for up to
"I believe strongly in Burcon's technology, commercial progress, and long-term growth potential," said James Pekar, "The Company has made meaningful strides in establishing its commercial business, and I am confident in the opportunity ahead. My continued financial support reflects that conviction and provides additional working capital as Burcon executes its growth strategy and advances its broader financing plans."
Financial Results (in Canadian dollars)
In the three and six months ended September 30, 2026, Burcon generated revenue of
In the six months ended September 30, 2026, the Company reported net cash used in operating activities of
As of September 30, 2026, Burcon had
For full details on the Company's financial results, refer to the condensed consolidated interim financial statements for the three and six months ended September 30, 2026 and management's discussion and analysis for such period filed on SEDAR+ at www.sedarplus.ca.
Short-Term Loan
Today, Burcon announces it has entered into a loan agreement (the "Loan Agreement") for up to
The Loan matures on November 16, 2027. The Lender will be paid a commitment fee of
The Loan is considered a "related party transaction" pursuant to Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). Burcon is relying on the exemption from the minority shareholder approval requirement available under Section 5.7(1)(f) of MI 61-101. Additionally, the Loan is not subject to the formal valuation requirement of MI 61-101 because it falls within paragraph (j) of the definition of "related party transaction". The Loan Agreement was approved by the independent directors of the board of directors of Burcon, with the interested director abstaining from the vote.
Conference Call Details
The Company will hold an investor conference call and webcast on Monday, November 16, 2026 at 5:00 p.m. Eastern time.
A link to the webcast of the conference call will be available on Burcon's website under "Presentations" or directly here. The webcast will also be archived for future playback.
Investors interested in participating in the live call can dial in using the details below:
Date: Monday, November 16, 2026
Time: 5:00 p.m. Eastern time
Toll-free dial-in (North America): 1-800-717-1738
Dial-in (toll/international): 1-646-307-1865
Conference ID: 50194
About Burcon NutraScience Corporation
Burcon is a global technology leader in plant-based proteins for food and beverage applications. The Company has developed a portfolio of high-performance protein ingredients, including Peazzaz® pea proteins, FavaPro® fava proteins and Puratein® canola proteins, and is focused on commercializing its technologies through manufacturing partnerships and growing customer adoption worldwide.
Forward-Looking Information Cautionary Statement
The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements or forward-looking information can be identified by words such as "anticipate," "aim", "intend," "plan," "goal," "project," "estimate," "expect," "believe," "future," "likely," "may," "should," "could," "will" and similar references to future periods. All statements included in this release, other than statements of historical fact, are forward-looking statements. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon's plans and expectations include the implementation of our business model and growth strategies; trends and competition in our industry our future business development, financial condition and results of operations and our ability to obtain financing cost-effectively; potential changes of government regulations, and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled "Risk Factors" in Burcon's annual information form for the year ended March 31, 2026 and its other public filings with Canadian securities regulators on SEDAR+ at www.sedarplus.ca. This list is not exhaustive of the factors that may affect any of the Company's forward-looking statements or information. Any forward-looking statement or information speaks only as of the date on which it was made, and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and, accordingly, investors should not rely on such statements.
Industry and Investor Contact:
Investor Relations and Communications
Burcon NutraScience Corporation
720 - 999 West Broadway, Vancouver, BC, V5Z 1K5
Tel (604) 733-0896
info@burcon.ca
www.burcon.ca
Media Contact:
Steve Campbell, APR
President
Campbell & Company Public Relations
Tel (604) 888-5267
TECH@CCOM-PR.COM

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/324381
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much did Burcon's fiscal 2027 second-quarter revenue grow?
Burcon's second-quarter revenue increased approximately 191% year over year to C$1,040,829. For the six months ended September 30, 2026, revenue increased approximately 231% to C$2,317,041, driven by increased protein sales as commercial production ramped at the Galesburg facility.